Calloway, Jr. v. Moubarek

CourtDistrict Court, D. Maryland
DecidedNovember 30, 2020
Docket1:20-cv-01953
StatusUnknown

This text of Calloway, Jr. v. Moubarek (Calloway, Jr. v. Moubarek) is published on Counsel Stack Legal Research, covering District Court, D. Maryland primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Calloway, Jr. v. Moubarek, (D. Md. 2020).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF MARYLAND

ROBERT E. CALLOWAY, JR., *

Plaintiff, *

v. * CIVIL ACTION NO. GLR-20-1953

DR. MOHAMED MOUBAREK, *

Defendant. * *** MEMORANDUM OPINION THIS MATTER is before the Court on Defendant Mohamed Moubarek, M.D.’s Response to Order to Show Cause and Motion to Dismiss or, in the Alternative, Motion for Summary Judgment (ECF No. 6). The Motion is ripe for disposition, and no hearing is necessary. See Local Rule 105.6 (D.Md. 2018). For the reasons outlined below, the Court will grant Moubarek’s Motion, construed as one for summary judgment. I. BACKGROUND A. Plaintiff’s Allegations Plaintiff Robert E. Calloway, Jr. is a federal inmate presently housed at the Federal Correctional Institution in Cumberland, Maryland (“FCI-Cumberland”). (Compl. at 2, ECF No. 1). He alleges that he suffers from kidney disease and that Defendant Mohamed Moubarek, M.D., has refused to send him to a specialist or provide necessary medical treatment in violation of his Eighth Amendment rights. (Id. at 5). He seeks injunctive relief “compelling Moubarek to provide [him] with constitutionally adequate medical care for [his] chronic kidney disease by ensuring that [he is] treated by a specialist able to treat kidney disease and related ‘high critical’ medical concerns regarding [his] ‘creatinine’ level.” (Id. at 6).

On June 22, 2020, Calloway sent an email to the Director of Health Services, which he characterized as an initial administrative grievance, stating that he needed immediate treatment for his kidney disease and asking to see a specialist. (Pl.’s Exhs. at 10, ECF No. 8-1). On July 28, 2020, he sent a second email to Health Services inquiring about the status of his grievance. (Id. at 9). Calloway states that he intends to pursue his grievance throughout each stage of the Administrative Remedy Program (“ARP”). (Calloway Decl.

at 7, ECF No. 8). B. Defendant’s Response 1. Medical Care Calloway suffers from Chronic Kidney Disease (“CKD”), which Defendant Mohamed Moubarek M.D., Clinical Director of FCI-Cumberland, describes as a

progressive disease. (Moubarek Decl. ¶¶ 1, 4, ECF No. 6-2). CKD is categorized into five stages that correspond to the severity of the disease. (Id. ¶ 5). The disease is managed by controlling its signs and symptoms, reducing complications, and slowing its progression. (Id. ¶ 4). Management includes monitoring and controlling vital signs and blood work and treating the underlying conditions, such as high blood pressure and diabetes mellitus. (Id.).

Moubarek explains that in healthy patients, kidneys maintain creatinine in a normal range. (Id. ¶ 6). When the kidneys are impaired, the creatinine level in the blood rises because the kidneys have poor clearance. (Id.). High levels of creatinine in the blood is a warning of possible kidney malfunction or failure. (Id.). Kidney function is more precisely measured by calculating how much creatinine is cleared from the body by the kidneys, a calculation referred to as creatinine clearance. (Id.). Creatinine clearance estimates the rate

of filtration by kidneys, a rate referred to as the glomerular filtration rate (“GFR”). (Id.). Moubarek further explains that GFR is the best measure of kidney function and the GFR number is used to determine a person’s stage of CKD: Stage One has a GFR greater than ninety milliliters per minute; Stage Two (Mild CKD) has a GFR of sixty to eighty- nine milliliters per minute; Stage Three (Moderate CKD) has a GFR of thirty to fifty-nine milliliters per minute; Stage Four (Severe CKD) has a GFR of fifteen to twenty-nine

milliliters per minute; and Stage Five (End-Stage CKD) has a GFR less than fifteen milliliters per minute. (Id. ¶ 6). A GFR under sixty milliliters per minute is abnormal for adults. (Id. ¶ 6). When a patient’s GFR is less than thirty milliliters per minute, i.e., in the case of Severe CKD, a referral to a nephrologist is indicated. (Id.). On May 28, 2019, Calloway entered the Bureau of Prisons (“BOP”) and was

assigned to FCI-Cumberland. (Id. ¶ 8). Laboratory tests taken on June 18, 2019, showed he had possible CKD as his GFR was forty-four milliliters per minute. (Id. at 7).1 On July 2, 2019, Calloway was evaluated by Kristi Crites, C.R.N.P., who diagnosed Calloway with diabetes, CKD, hyperlipidemia, and hypertension. (Id. ¶ 10; pp. 14–17). He was prescribed medications to control his hypertension and hyperlipidemia and placed in

chronic care clinics so that he would be seen by medical providers at least every six months.

1 Calloway states that he had blood work on May 11, 2018 by the State of Ohio and on September 11, 2018, when he entered a BOP holding facility, neither of which showed signs of CKD. (Calloway Decl. at 6). (Id. ¶ 10). He was advised he could also make appointments as needed through the sick call process. (Id.). Crites ordered laboratory work and an ultrasound of Calloway’s kidneys.

(Id. at 16). The laboratory tests showed a GFR of thirty-eight milliliters per minute. (Id. at 9). On August 9, 2019 and November 22, 2019, imaging of Calloway’s kidneys showed he was missing his right kidney and had a small left kidney, suggesting that he had CKD for many years prior to entering the BOP. (Id. ¶ 9; pp. 11–12).2 Calloway had additional lab work performed on November 25, 2019, February 25,

2020, May 12, 2020, June 11, 2020, and June 24, 2020. (Id. ¶ 11; pp. 19–23). On each occasion, his GFR was above thirty milliliters per minute, meaning that his CKD remained moderate. (Id.). Following a clinical encounter with Calloway on November 26, 2019, Crites noted that he should be sent to a nephrologist due to elevated creatinine and a GFR of thirty-four

milliliters per minute. (Id. ¶ 12; p. 25). While waiting for the appointment, however, his kidney function improved and his blood pressure came under control. (Id. ¶ 12). As a result, the appointment was cancelled. (Id.). Moubarek met with Calloway on June 18, 2020. (Id. at 29). Moubarek noted that Calloway suffers from: asymptomatic Type II diabetes; hypertension and hyperlipidemia,

which were being treated pharmacologically; and Stage Three CKD, with a GFR of forty-

2 Calloway notes that in early 2011 he was to be a kidney donor for his mother, but he was unable to complete the process due to his incarceration, and states his belief that he had two functioning kidneys at that time. (Calloway Decl. at 3). seven milliliters per minute. (Id. ¶ 13; p. 29). Moubarek counseled Calloway regarding compliance with his prescribed medications and added a prescription of Lisinopril for kidney protection and to treat Calloway’s high blood pressure. (Id. ¶ 13; p. 31).3

FCI-Cumberland is a Medical Care Level Two institution that, according to Moubarek, is appropriate for Calloway’s current stage of CKD. (Id. ¶ 14). Inmates are designated to a Medical Care Level Three institution if they have CKD with a GFR less than thirty milliliters per minute, but do not yet require dialysis. (Id. ¶ 14; p. 35). Moubarek avers that if Calloway’s condition worsens, he will be scheduled to see a nephrologist

and/or moved to a higher medical care institution. (Id. ¶ 14). 2. Administrative Filings As of July 16, 2020, Calloway had filed two administrative grievances during his incarceration in the BOP. (Williams Decl. ¶ 5, ECF No. 6-3). Neither grievance concerned the care of his CKD or a request to be transferred to a higher medical care institution. (Id.).

On November 18, 2019, Calloway filed a grievance regarding denial of access to his medical records, including ultrasound results. (Id. at 5).4 On July 2, 2020, he filed a grievance about being moved to another cell. (Id.).

3 Calloway contends that this medication should not have been prescribed to him since he suffers from CKD. (Calloway Decl. at 4).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Adickes v. S. H. Kress & Co.
398 U.S. 144 (Supreme Court, 1970)
Gregg v. Georgia
428 U.S. 153 (Supreme Court, 1976)
Estelle v. Gamble
429 U.S. 97 (Supreme Court, 1976)
Anderson v. Liberty Lobby, Inc.
477 U.S. 242 (Supreme Court, 1986)
Wilson v. Seiter
501 U.S. 294 (Supreme Court, 1991)
Hudson v. McMillian
503 U.S. 1 (Supreme Court, 1992)
Miller v. French
530 U.S. 327 (Supreme Court, 2000)
Porter v. Nussle
534 U.S. 516 (Supreme Court, 2002)
Hope v. Pelzer
536 U.S. 730 (Supreme Court, 2002)
Woodford v. Ngo
548 U.S. 81 (Supreme Court, 2006)
Jones v. Bock
549 U.S. 199 (Supreme Court, 2007)
Munaf v. Geren
553 U.S. 674 (Supreme Court, 2008)
Ricci v. DeStefano
557 U.S. 557 (Supreme Court, 2009)
United States v. Clawson
650 F.3d 530 (Fourth Circuit, 2011)

Cite This Page — Counsel Stack

Bluebook (online)
Calloway, Jr. v. Moubarek, Counsel Stack Legal Research, https://law.counselstack.com/opinion/calloway-jr-v-moubarek-mdd-2020.